医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

NCKU Research Team Reveals Key Mechanism in Lung Cancer

2014年09月25日 PM06:29
このエントリーをはてなブックマークに追加


 

TAINAN, Taiwan

Lung cancer remains one of the most common and malignant cancers worldwide. A Tainan-based research team from National Cheng Kung University (NCKU) has discovered Rab37, a protein in humans which is a critical regulator of vesicle trafficking, has played a vital role in inhibition of cancer metastasis.

The team led by NCKU Distinguished Professor Dr. Yi-Ching Wang from the Department of Pharmacology and Institute of Basic Medical Science, College of Medicine, made major medical breakthrough in tumour treatment, the university revealed at a press conference in Taipei on September 25.

Their research titled “Small GTPase Rab37 targets tissue inhibitor of metalloproteinase 1 for exocytosis and thus suppresses tumour metastasis” has been published in the September issue of Nature Communications.

“What we’ve discovered will help clinicians to better treat patients with lung cancer,” said Dr. Wang.

She noted that Rab-controlled trafficking pathways have been involved in tumorigenesis.

She also explained, Rab37 suppresses metastasis by regulating the exocytosis of tissue inhibitor of metalloproteinase 1 (TIMP1) to repress matrix metalloproteinase 9 (MMP9) and represents a novel prognostic marker for lung cancer.

“We address the metastasis suppressive function of Rab37 using secretomics, cell, animal and clinical analyses,” Dr. Wang added.

The study shows that TIMP1is a novel cargo of Rab37, according to Dr. Wang, and lung cancer patients with metastasis show low Rab37 protein expression coinciding with low TIMP1 in tumours.

Dr. Wang’s team has identified Rab37 as a novel metastasis suppressor Rab that functions through the TIMP1-MMP9 pathway and has significant prognostic power.

CONTACT

National Cheng Kung University
Sonia Chuang, +886-6-275-7575 Ext.
50042
News Center
sonia20@mail.ncku.edu.tw
Fax:
+886-6-238-9919
NCKU news: http://news-en.secr.ncku.edu.tw/bin/home.php

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc